Jean-Francois DEDIEU et al. Serial No. 09/654,223

Attorney Docket No. 08888.1129

## **IN THE DRAWINGS:**

Subject to the approval of the Examiner, please replace Figures 1 and 2, as filed with this reissue application, with the enclosed Figures 1 and 2.

## IN THE CLAIMS:

Please amend claims 2-14 as follows:

- 2. (Twice Amended) [An] <u>The</u> adenovirus according to claim 1, wherein the EBV antigen is EBNA 1.
- 3. (Amended) [An] <u>The</u> An adenovirus according to claim 2, wherein the expression signal consists of a chimeric promoter comprising a sequence which is activated by EBNA 1 antigen fused upstream of a viral promoter.
- 4. (Amended) [An] <u>The</u> adenovirus according to claim 1, lacking regions of its genome which are required for replication in a target cell.
- 5. (Amended) [An] <u>The</u> adenovirus according to claim 4, wherein said adenovirus is a type Ad5 human adenovirus or a type CAV-2 canine adenovirus.
- 6. (Amended) [An] <u>The</u> adenovirus according to claim 1, wherein the heterologous DNA sequence comprises a gene which encodes a product toxic in a cell infected by said adenovirus.
- 7. (Amended) [An] <u>The</u> adenovirus according to claim 6, wherein said product renders said cell sensitive to a therapeutic agent.
- 8. (Amended) [An] <u>The</u> adenovirus according to claim 7, wherein the gene is the thymidine kinase gene and the therapeutic agent is ganciclovir or acyclovir.

AZ

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

1300 l Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com

445008\_1